StocksFundsScreenerSectorsWatchlists
IGC

IGC - India Globalization Capital Inc Stock Price, Fair Value and News

0.46USD-0.03 (-6.12%)Delayed as of 22 Apr 2024, 03:03 pm ET

Market Summary

IGC
USD0.46-0.03
Delayedas of 22 Apr 2024, 03:03 pm
-6.12%

IGC Stock Price

View Fullscreen

IGC RSI Chart

IGC Valuation

Market Cap

31.2M

Price/Earnings (Trailing)

-2.21

Price/Sales (Trailing)

90.19

EV/EBITDA

-2.22

Price/Free Cashflow

-5.05

IGC Price/Sales (Trailing)

IGC Profitability

Operating Margin

-178.54%

EBT Margin

-6672.17%

Return on Equity

-156.18%

Return on Assets

-125.58%

Free Cashflow Yield

-19.82%

IGC Fundamentals

IGC Revenue

Revenue (TTM)

212.0K

Rev. Growth (Yr)

-38.55%

Rev. Growth (Qtr)

-29.9%

IGC Earnings

Earnings (TTM)

-14.1M

Earnings Growth (Yr)

-148.51%

Earnings Growth (Qtr)

-128.03%

Breaking Down IGC Revenue

52 Week Range

0.280.51
(Low)(High)

Last 7 days

11.4%

Last 30 days

44.1%

Last 90 days

75%

Trailing 12 Months

32.3%

How does IGC drawdown profile look like?

IGC Financial Health

Current Ratio

1.85

Debt/Equity

0.02

Debt/Cashflow

-44.86

IGC Investor Care

Shares Dilution (1Y)

20.08%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2023212.0K000
2022397.0K532.0K678.0K868.0K
2021898.0K391.0K322.0K356.0K
20204.1M3.0M1.3M846.0K
20195.1M5.3M6.3M5.6M
20182.2M3.6M4.2M4.7M
2017793.5K557.9K630.7K1.1M
20166.4M4.8M2.9M2.1M
20157.7M8.8M8.7M7.3M
20142.3M3.6M5.0M6.3M
20138.0M7.9M7.7M3.8M
20124.2M4.4M4.8M7.8M
20114.1M4.0M3.2M3.7M
201017.9M14.4M11.0M7.5M

Tracking the Latest Insider Buys and Sells of India Globalization Capital Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Mar 13, 2024
mukunda ram
acquired
-
-
1,151,250
ceo
Mar 13, 2024
prins richard k
acquired
-
-
329,583
-
Mar 13, 2024
mukunda ram
gifted
-
-
-200,000
ceo
Mar 13, 2024
moran james p
acquired
-
-
220,834
-
Mar 13, 2024
mukunda ram
acquired
-
-
33,334
ceo
Mar 13, 2024
grimaldi claudia
acquired
-
-
336,666
-
Jun 23, 2023
mukunda ram
gifted
-
-
-400,000
ceo
Mar 31, 2023
moran james p
acquired
-
-
83,334
-
Mar 31, 2023
prins richard k
acquired
-
-
158,334
-
Mar 31, 2023
mukunda ram
acquired
-
-
33,334
ceo

1–10 of 50

Which funds bought or sold IGC recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Apr 12, 2024
Game Plan Financial Advisors, LLC
sold off
-100
-140
-
-%
Apr 11, 2024
DHJJ Financial Advisors, Ltd.
unchanged
-
9.00
32.00
-%
Mar 11, 2024
VANGUARD GROUP INC
unchanged
-
-51,097
180,711
-%
Mar 01, 2024
GOLDMAN SACHS GROUP INC
added
100
13,157
36,690
-%
Feb 26, 2024
Virtu Financial LLC
reduced
-13.25
-8,000
17,000
-%
Feb 15, 2024
JANE STREET GROUP, LLC
sold off
-100
-16,722
-
-%
Feb 14, 2024
BRIDGEWAY CAPITAL MANAGEMENT, LLC
unchanged
-
-5,465
19,327
-%
Feb 14, 2024
MILLENNIUM MANAGEMENT LLC
sold off
-100
-5,129
-
-%
Feb 14, 2024
SUSQUEHANNA INTERNATIONAL GROUP, LLP
added
40.92
1,932
21,532
-%

1–10 of 34

Are Funds Buying or Selling IGC?

Are funds buying IGC calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own IGC
No. of Funds

Recent SEC filings of India Globalization Capital Inc

View All Filings
Date Filed Form Type Document
Apr 18, 2024
S-3
S-3
Apr 05, 2024
8-K
Current Report
Mar 28, 2024
8-K
Current Report
Mar 22, 2024
8-K
Current Report
Mar 22, 2024
424B5
Prospectus Filed
Mar 18, 2024
4
Insider Trading
Mar 15, 2024
4
Insider Trading
Mar 15, 2024
4
Insider Trading
Mar 15, 2024
4
Insider Trading
Mar 15, 2024
4
Insider Trading

Peers (Alternatives to India Globalization Capital Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
38.7B
6.8B
-1.66% -28.18%
-8.22
5.66
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
18.2B
1.8B
-2.46% -28.84%
-41.3
9.94
76.23% 61.08%
16.7B
2.4B
4.57% -8.46%
99.75
6.91
15.42% 18.43%
11.8B
3.7B
-10.11% -29.11%
19.67
3.18
8.87% 75.42%
MID-CAP
5.7B
396.6M
-14.37% -42.33%
-10.84
14.45
425.83% 18.94%
4.4B
-
-13.59% 50.21%
-6.66
60.35
54.84% -34.79%
3.2B
270.6M
-13.81% -4.67%
-13.45
11.89
440.80% -27.84%
2.8B
726.4M
-9.91% -15.82%
-45.22
3.82
40.45% 71.62%
2.8B
240.7M
-20.67% -25.33%
-9.32
12.18
-1.03% -92.09%
SMALL-CAP
1.8B
398.2M
-10.64% -8.42%
24.94
4.47
85.90% -14.05%
558.4M
983.7M
-17.39% -51.52%
-1.02
0.57
-50.36% 17.16%
409.4M
881.7K
-0.38% 387.14%
-9.18
466.16
-77.61% -5.33%
226.2M
4.9M
-10.29% -2.81%
-1.67
46.49
-54.97% 51.71%
6.0M
2.1M
59.81% 33.59%
-0.22
2.14
-13.45% 66.37%

India Globalization Capital Inc News

Latest updates
TipRanks • 05 Apr 2024 • 03:46 pm
InvestorsObserver • 20 Mar 2024 • 07:00 am

India Globalization Capital Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue-29.9%204,000291,000555,000443,500332,000202,000212,000122,000142,00056,00077,00081,000108,000125,000584,00029,000573,0001,821,0001,649,0001,542,0001,285,000
Cost Of Revenue-39.3%71,000117,000300,000102,500230,00067,00070,00054,00080,00018,00051,00054,00094,00099,000538,00013,000543,0001,793,0001,608,0001,515,0001,240,000
Gross Profit-23.6%133,000174,000255,00063,000102,000135,000142,00068,00062,00038,00026,00027,00014,00026,00046,00016,00030,00028,00041,00027,00045,000
  S&GA Expenses59.5%2,228,0001,397,0001,647,0003,591,0001,574,0001,855,0001,550,0005,336,0002,070,0004,110,0001,776,0002,484,0002,186,0001,483,0001,755,0002,212,0001,413,0001,094,0001,249,0001,582,000807,000
  R&D Expenses-28.8%903,0001,268,000747,000493,000806,000768,0001,394,0001,203,000377,000276,000444,000334,000154,000219,000222,000247,000295,000222,000247,000793,500166,000
EBITDA Margin-33.0%-63.77-47.96-47.86-51.17-15.33-19.83-28.87-36.18-30.37-33.51-20.87-9.28---------
Interest Expenses----------------2,0002,0002,0002,0002,0003,000
Income Taxes--------------------2,000-
Earnings Before Taxes-128.0%-5,589,000-2,451,000-2,075,000-4,030,000-2,249,000-2,442,000-2,785,000-6,503,000-2,381,000-4,344,000-1,788,000-2,949,000-2,323,000-1,657,000-1,882,000-3,154,000-1,603,000-1,179,000-1,379,000-1,576,000-1,148,000
EBT Margin-30.9%-66.72-50.97-50.92-54.27-16.10-20.81-30.10-37.82-32.20-35.42-22.29-9.81---------
Net Income-128.0%-5,589,000-2,451,000-2,075,000-4,024,000-2,249,000-2,442,000-2,785,000-6,503,000-2,381,000-4,344,000-1,788,000-2,949,000-2,323,000-1,657,000-1,882,000-3,154,000-1,603,000-1,179,000-1,379,000-1,578,000-1,148,000
Net Income Margin-30.9%-66.72-50.97-50.92-54.27-16.09-20.79-30.07-37.78-32.20-35.42-22.29-9.81---------
Free Cashflow1.9%-1,587,000-1,618,000-1,488,000-1,644,000-1,775,000-1,813,000-2,323,000-971,000-2,449,000-2,334,000-1,944,000-2,594,000-1,997,000--------
Balance Sheet
(In Thousands)
Balance Sheet
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets-31.8%11,25916,50615,67317,17820,07021,95824,16626,83431,28833,83634,44435,86724,16326,34628,29928,98431,10232,88733,50534,46537,159
  Current Assets-41.4%3,5836,1175,0786,4669,35411,19912,72715,11119,23721,70422,19023,51711,42113,68716,00217,75720,50623,90024,57426,72328,160
    Cash Equivalents-54.5%1,3783,0261,7233,1964,9456,6238,05310,46011,94114,39913,31914,5489681,1512,7037,25810,12914,06316,55425,61027,033
  Inventory-27.0%1,9252,6362,6412,6513,7483,7503,6223,5485,4285,4985,4765,4785,1566,6846,5234,2453,5853,1081,970248-
  Net PPE-33.7%5,2687,9478,1048,2138,3098,4709,1619,41910,52010,58910,70410,84010,96810,90610,6039,7808,6877,1237,0555,8865,864
Liabilities-8.4%2,2062,4082,4712,2671,7531,8142,1262,9421,8132,5802,7073,0642,6912,7483,4362,4471,3161,6451,085893598
  Current Liabilities-8.1%1,9362,1062,1311,8981,3561,3821,6592,4411,2792,0152,1122,3681,9181,8982,3191,9461,3011,6301,070878534
  Short Term Borrowings-------3.003.003.003.003.00304252196-50.0050.0050.0050.0050.00-
  Long Term Debt-0.7%138139140141141142143144145146147276328384630------
    LT Debt, Non Current-0.7%138139140141141142143144145146147276328384630------
Shareholder's Equity-35.8%9,05314,09813,20214,91118,31720,14422,04023,89229,47531,25631,73732,80321,47223,59824,86326,53729,78631,24232,42033,57236,561
  Retained Earnings-5.3%-110,780-105,191-102,740-100,665-96,635-94,386-91,944-89,159-82,656-80,275-75,931-74,143-71,229-68,906-67,249-65,367-62,213-60,610-59,431-58,052-56,315
Shares Outstanding0.0%63,73463,70753,07753,07753,07753,05851,84151,05451,05451,04148,28447,827---------
Float------20,813---70,376---38,047---34,795---
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations1.9%-1,587-1,618-1,468-1,517-1,648-1,686-2,196-887-2,422-2,302-1,851-2,505-1,845-2,462-3,988-1,993-2,240-1,572-2,872-1,148-1,331
  Share Based Compensation-4.4%5265503575834846241,1521,12552342412513515819916624616315320895.0013.00
Cashflow From Investing-184.7%-61.0072.00-5.00-242-17.00182-158-553-49.00-45.00-95.001,9281,654941-1,136-741-1,695-925-6,186-211-33.00
Cashflow From Financing-100.0%-1.002,859-1.00-1.00-102-1.00-1.00-1.003,41872614,158--50.00580-77.00-18.00--7.0021,922

IGC Income Statement

2023-12-31
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2023
Dec. 31, 2022
Income Statement [Abstract]    
Revenue$ 204$ 332$ 1,050$ 745
Cost of revenue(71)(230)(488)(366)
Gross profit133102562379
Selling, General and Administrative expenses(2,228)(1,574)(5,272)(4,943)
Research and development expenses(903)(806)(2,918)(2,968)
Operating loss(2,998)(2,278)(7,628)(7,532)
Impairment Loss on PPE(2,623)0(2,623)0
Other income, net322913656
Loss before income taxes(5,589)(2,249)(10,115)(7,476)
Income tax expense/benefit0000
Net loss attributable to common stockholders(5,589)(2,249)(10,115)(7,476)
Foreign currency translation adjustments18(61)(36)(462)
Comprehensive loss$ (5,571)$ (2,310)$ (10,151)$ (7,938)
Net loss per share attributable to common stockholders:    
Basic and diluted (in Dollars per share)$ (0.09)$ (0.04)$ (0.18)$ (0.14)
Weighted-average number of shares used in computing net loss per share amounts: (in Shares)63,725,08453,063,47357,039,03552,412,830

IGC Balance Sheet

2023-12-31
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2023
Mar. 31, 2023
Current assets:  
Cash and cash equivalents$ 1,378$ 3,196
Accounts receivable, net92107
Short term investments 154
Inventory1,9252,651
Deposits and advances188358
Total current assets3,5836,466
Non-current assets:  
Intangible assets, net1,1821,170
Property, plant, and equipment, net5,2688,213
Claims and advances9991,003
Operating lease asset227326
Total non-current assets7,67610,712
Total assets11,25917,178
Current liabilities:  
Accounts payable648530
Accrued liabilities and others1,2881,368
Total current liabilities1,9361,898
Non-current liabilities:  
Long-term loans138141
Other liabilities1721
Operating lease liability115207
Total non-current liabilities270369
Total liabilities2,2062,267
Commitments and Contingencies – See Note 12
Stockholders’ equity:  
Preferred stock, $0.0001 par value: authorized 1,000,000 shares, no shares issued or outstanding as of December 31, 2023, and March 31, 2023.00
Common stock and additional paid-in capital, $0.0001 par value: 150,000,000 shares authorized; 63,734,439 and 53,077,436 shares issued and outstanding as of December 31, 2023, and March 31, 2023, respectively.123,258118,965
Accumulated other comprehensive loss(3,425)(3,389)
Accumulated deficit(110,780)(100,665)
Total stockholders’ equity9,05314,911
Total liabilities and stockholders’ equity$ 11,259$ 17,178
IGC
IGC Pharma, Inc., a clinical stage biotechnology company, engages in developing cannabinoid-based formulations for treating diseases and conditions, including Alzheimer's disease, dysmenorrhea, premenstrual syndrome, and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease comprising IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63 that is in pre-clinical development. It also markets Holief, a wellness brand that targets women experiencing premenstrual syndrome and menstrual cramps. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland.
 CEO
 WEBSITEhttps://igcpharma.com
 INDUSTRYBiotechnology
 EMPLOYEES61

India Globalization Capital Inc Frequently Asked Questions


What is the ticker symbol for India Globalization Capital Inc? What does IGC stand for in stocks?

IGC is the stock ticker symbol of India Globalization Capital Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of India Globalization Capital Inc (IGC)?

As of Fri Apr 19 2024, market cap of India Globalization Capital Inc is 31.23 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of IGC stock?

You can check IGC's fair value in chart for subscribers.

What is the fair value of IGC stock?

You can check IGC's fair value in chart for subscribers. The fair value of India Globalization Capital Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of India Globalization Capital Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for IGC so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is India Globalization Capital Inc a good stock to buy?

The fair value guage provides a quick view whether IGC is over valued or under valued. Whether India Globalization Capital Inc is cheap or expensive depends on the assumptions which impact India Globalization Capital Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for IGC.

What is India Globalization Capital Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 19 2024, IGC's PE ratio (Price to Earnings) is -2.21 and Price to Sales (PS) ratio is 90.19. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. IGC PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on India Globalization Capital Inc's stock?

In the past 10 years, India Globalization Capital Inc has provided -0.052 (multiply by 100 for percentage) rate of return.